Induced Pluripotent stem cells (iPSC) technology was first introduced in 2006 by Shinya Yamanaka’s laboratory in Kyoto, Japan. These cells are a type of induced Pluripotent cells those can be directly generated from the adult (fully grown) cells. This discovery holds massive hope in the practice of regenerative medicine; they can definitely propagate and give rise to each kind of a cell type in the body such as the liver, heart, neurons and so on.
Major iPSC Market Forces:
The first iPSCs investigation involving humans started in August, 2013. The aim of the study is to know the use of iPSCs in treating human molecular degeneration. This study is lead by Masaya Takahashi at the Riken Center in Japan.
Post 2014, funding in the forms of research grants and public stock offering for such studies have aggressively increased. Survey indicates that 22% of the Steam Cell researchers now sel-report with their projects, this has been possible due to their iPSC project experiences.
A pharma group known as the “Biogatekeeper” is challenging the ownership rights of the popular ‘Yamanaka Patent’ (USA Patent no: 8,058,065). This patent was done for the cellular programming of iPSCs, in case of the Biogatekeeper group winning the lawsuit, this would be a great revolution in the field innovative stem cell sector; this will allow low costs iPSC products,
Creation of Disease Specific iPSC Lines:
At present there are 26 clinical studies carried on in different regions of the world in order to create better iPSC technology and product lines. Details are as follows in the Infographic.